Issues - Novembre 2024

Phillips KA, Kotsopoulos J, Domchek SM, et al.

Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2

J Clin Oncol 2024 Oct 2:JCO2400176. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Wu AH, Wu J, Tseng C, et al.

Air pollution and breast cancer incidence in the multiethnic cohort study

J Clin Oncol 2024 Oct 8:JCO2400418. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Kim DH, Théberge V, Parpia S, et al.

OPAR: a randomized trial of partial breast irradiation in five fractions once daily for early breast cancer

J Clin Oncol 2024 Oct 8:JCO2400600. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Turner N, Saura C, Aftimos p, et al.

Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)

J Clin Oncol 2024 Oct 23:JCO2400529. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Jensen MB, Balslev E, Knoop AS, et al.

Adjuvant docetaxel and cyclophosphamide with or without epirubicin for early breast cancer: final analysis of the randomized DBCG 07-READ trial

J Clin Oncol 2024 Oct 23:JCO2400836. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract | Scarica ppt

---

Hortobagyi GN, Lacko A, Sohn J, et al.

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ann Oncol 2024 Oct 21:S0923-7534(24)04064-X. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Hiensch AE, Depenbusch J, Schmidt ME, et al.

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

Nat Med 2024;30(10):2957-2966

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Watts EL, Moore SC, Abar L, et al.

Physical activity, metabolites, and breast cancer associations

J Natl Cancer Inst 2024 Oct 9:djae246. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

John EM, Koo J, Ingles SA, et al.

Risk factors for second primary breast cancer by laterality, age, and race and ethnicity

J Natl Cancer Inst 2024 Oct 11:djae254. Epub ahead of print

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Nader-Marta G, Singer C, Hlauschek D, et al.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Breast Cancer Res 2024;26(1):140

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gjesvik J, Moshina N, Lee CI, et al.

Artificial intelligence algorithm for subclinical breast cancer detection

JAMA Netw Open 2024;7(10):e2437402

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gannon MR, Dodwell D, Miller K, et al.

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: a national population-based cohort study using routine data

Eur J Cancer 2024;211:114309

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Kimmick G, Pilehvari A, You W, et al.

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting

Breast Cancer Res Treat 2024;208(2):263-273

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Pilehvari A, Kimmick G, You W, et al.

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting

Breast Cancer Res 2024;26(1):144

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---